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Aflatoxin B1 (AFB1) and/or hepatitis B and C viruses are risk factors
for human hepatocellular carcinoma (HCC). Available evidence sup-
ports the interpretation that formation of AFB1-DNA adducts in he-
patocytes seeds a population of mutations, mainly G:C→T:A, and
viral processes synergize to accelerate tumorigenesis, perhaps via
inflammation. Responding to a need for early-onset evidence pre-
dicting disease development, highly accurate duplex sequencing was
used to monitor acquisition of high-resolution mutational spectra
(HRMS) during the process of hepatocarcinogenesis. Four-day-old
male mice were treated with AFB1 using a regimen that induced
HCC within 72 wk. For analysis, livers were separated into tumor
and adjacent cellular fractions. HRMS of cells surrounding the tumors
revealed predominantly G:C→T:A mutations characteristic of AFB1
exposure. Importantly, 25% of all mutations were G→T in one tri-
nucleotide context (CGC; the underlined G is the position of the
mutation), which is also a hotspot mutation in human liver tumors
whose incidence correlates with AFB1 exposure. The technology
proved sufficiently sensitive that the same distinctive spectrum
was detected as early as 10 wk after dosing, well before evidence
of neoplasia. Additionally, analysis of tumor tissue revealed a more
complex pattern than observed in surrounding hepatocytes; tumor
HRMS were a composite of the 10-wk spectrum and a more hetero-
geneous set of mutations that emerged during tumor outgrowth.
We propose that the 10-wk HRMS reflects a short-term mutational
response to AFB1, and, as such, is an early detection metric for AFB1-
induced liver cancer in this mouse model that will be a useful tool to
reconstruct the molecular etiology of human hepatocarcinogenesis.
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Hepatocellular carcinoma (HCC) is the third leading cause ofcancer death worldwide, responsible for ∼700,000 deaths
each year (1). Despite ample epidemiological evidence for
multiple chemical and viral risk factors, and opportunities to
mitigate such risks, HCC remains a particularly deadly disease
because it is relatively asymptomatic until the disease reaches a
very late stage. These considerations highlight the acute need for
early detection of mutagenic processes that initiate and/or pro-
mote carcinogenesis in the liver.
The fungal toxin aflatoxin B1 (AFB1) represents one of the most
prevalent causative agents of HCC, especially in parts of the world
where people consume staple grains contaminated with the food
spoilage fungus, Aspergillus flavus, and are concurrently infected
with hepatitis viruses (2–4). AFB1 consumption and HCC are
epidemiologically linked in much of the developing world, in-
cluding Southeast Asia, China, and sub-Saharan Africa (5). AFB1
(Fig. 1) is a potent mutagen and carcinogen (International Agency
for Research on Cancer class I). Upon ingestion, it is rapidly
absorbed from the digestive tract, transported to the liver, and
absorbed by liver cells. There, the toxin is converted by phase I
enzymes, such as cytochrome P450 1A2 and 3A4 (6, 7), into me-
tabolites that include the exo-epoxide, which is the primary
chemical precursor to AFB1-mediated mutagenic and carcino-
genic events. This epoxide intercalates 5′ to guanine targets in
DNA before covalent bonding with the guanyl N7 atom (8), ulti-
mately forming a stereospecific AFB1-N
7-Gua adduct (Fig. 1). A
wide variation in adduct formation efficiency occurs across se-
quence space, which may reflect the mechanistic details of in-
tercalation and reaction of the epoxide with guanines in different
sequence contexts (9). The imidazole ring of the initial cationic
adduct is vulnerable to facile hydrolysis, leading to the ring-
opened AFB1 formamidopyrimidine (FAPY) adduct, a persis-
tent lesion that appears to stabilize the DNA helix, making it more
refractory to repair than its parent, AFB1-N
7-Gua (10, 11). Owing
to its persistence and high inherent mutability, the AFB1-FAPY
adduct likely accounts for the majority of the mutations induced
by aflatoxin (12); when traversed by replicative or translesion
polymerases, the AFB1-FAPY adduct causes primarily G→T
mutations. This defining mutation of AFB1 has been documented
following replication in vitro (12, 13), in cell culture (14), in animal
models (15, 16), and even in human specimens (17, 18).
Other risk factors synergize with AFB1 to induce HCC. The
incidence of HCC is particularly high in populations that, in
addition to exposure to dietary AFB1, are carriers of hepatitis
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B or C virus. Mechanisms underlying the carcinogenic synergy
between toxin exposure and viral infection, shown to be in excess
of 60-fold (19, 20), are not fully understood. One possible ex-
planation is that chronic infection-mediated inflammation, along
with inflammation from local AFB1-induced necrosis, can result
in the production of reactive oxygen species (21). Reactive
oxygen-induced damage is thus superimposed on AFB1 damage
to the genome in tissues exposed to the toxin. Moreover, in-
flammation may induce low-fidelity bypass polymerases and/or
cause failed attempts at DNA repair (22), which would induce
additional mutations. Ultimately, the mutational portrait of an
end-stage tumor likely reflects the contributions from the several
aforementioned mutagenic processes (Fig. 1), starting from the
founder mutational spectrum induced by AFB1 (spectrum 1 in
Fig. 1), which is diversified and enriched with additional muta-
tions (spectra 2 and 3 in Fig. 1) from inflammatory and/or viral
processes throughout malignant progression.
A well-established animal model for studying carcinogenicity of
environmental agents, including AFB1, is the B6C3F1 mouse (23);
a transgenic variant of this mouse (λ-gptΔ B6C3F1) was developed
to measure the amounts and types of mutations that arise in its
guanine phosphoribosyltransferase (gpt) mutational target. Al-
though this approach allows for robust estimations of mutational
frequencies, the biased nature of the selection process makes it
nonoptimal for construction of high-resolution mutational spectra
(HRMS) that reveal the sequence context dependence of muta-
genic processes. The present work expanded the utility of this
mouse model to characterize the acquisition and evolution of
mutational spectra during hepatocarcinogenesis. Our approach
focused analysis on an expanded mutational target (6.4 kb) by
using the recently developed duplex sequencing (DS) protocol
(24). Unlike conventional next-generation sequencing, which is
limited in its accuracy by the high rate of sequencing-introduced
artifacts, DS employs molecular barcoding of both strands of
DNA independently and a high sequencing depth, which affords
increases of three to four orders of magnitude in sequencing
fidelity over conventional sequencing technology. A similar strat-
egy of molecular barcoding and strand amplification to establish a
consensus sequence of DNA fragments has identified rare muta-
tions in genomic DNA of normal and cancer tissues (25). This
accuracy allowed for the detection of relatively rare mutations that
occur early following mutagen exposure (e.g., 10 wk after dosing),
as well as the dissection of the mutational complexity and the
degree of clonality of later stage tumors that arise from the
carcinogenic process.
By applying the DS strategy to the AFB1-treated mouse model,
HRMS were obtained that provide insight into the mutational
processes operative during the development of HCC. The AFB1-
specific mutational spectrum that appeared early after carcinogen
administration, and persisted until tumors developed over a year
later, displayed strong similarity to mutational spectra seen in a
frequent genetically related subset of human liver cancers. The
discovery of cancer-associated exposure mutational spectra that
appear long before the signs of malignancy will benefit the cancer
epidemiology and prevention communities.
Results
Liver Tumor Induction in B6C3F1 Mice by a Single Exposure to AFB1.
The carcinogenesis model used involved treatment of 4 d-old gptΔ
B6C3F1 male mice with a 6-mg/kg dose of AFB1 dissolved in
DMSO (Fig. 2A). The genetic consequences of carcinogen expo-
sure were evaluated at 10 wk, at which time no signs of patho-
genesis were evident, and at 72 wk, when grossly visible tumors
were present. Collagenase perfusion allowed separation of tumor
sectors from surrounding tissue. Mutational spectra at 10 wk are
designated A-10 (AFB1-treated) and D-10 (DMSO-treated).
Spectrum A-72T (T, tumor) is derived from isolated liver tu-
mors, whereas spectrum A-72H (H, hepatocytes) is from a he-
patocyte fraction surrounding the tumors from 72-wk-old AFB1-
treated animals (Fig. 2B). Lastly, D-72 denotes the spectrum of
72-wk-old livers from DMSO-treated control animals (Fig. 2A).
Use of DS to Generate HRMS of AFB1-Treated Mouse Livers. The
method in Fig. 2C shows how the conventional transgenic gptΔ
B6C3F1 mouse model was meshed with DS to reveal HRMS at-
tributable to AFB1. The gptΔ B6C3F1 mouse contains 40 copies of
a λ-phage vector carrying the gpt gene on chromosome 17 (26).
The mutations in the gpt cluster were isolated by recovery of
λ-sequences from the mouse liver via phage λ-packaging and in-
fection of resultant phage into bacteria, where CRE-LOX re-
combination formed plasmids that include the gpt gene within the
6.4-kb plasmid sequence. In the traditional application of the as-
say, mutations in the gpt gene are phenotypically enumerated by 6-
thioguanine resistance and characterized by conventional DNA
sequencing. However, the traditional gpt assay results are limited
in that mutations are detected only if they disrupt the functionality
of the GPT protein; thus, only a biased set of mutations (i.e., a
selected spectrum) in relatively few sequence contexts can be
identified (15, 16). By contrast, the DS strategy (Fig. 2C) cir-
cumvents these limitations by tagging and sequencing each of the
complementary strands of DNA independently. True mutations
(green dots in Fig. 2C) are identified computationally, after se-
quencing, as mutations that existed at the same site in each of the
independent strands that entered the sequencing run. One ad-
vantage of the new assay is the enlargement of the genetic target
from 459 bp to 6,382 bp. Second, the DSmethod allows readout of
mutations at all nucleotides in the target, not just those mutations
selectable in the conventional gpt assay. The gpt assay is biased
toward detection of mutations that affect the functional domains
of the gpt enzyme (e.g., the active site), and those biases confound
attempts to identify mutagen-induced mutational landscapes in
tissues exposed to exogenous or endogenous genotoxic agents. Fig.
S1 shows a “selected” mutational spectrum of AFB1 from Woo
et al. (16), which is strikingly different in landscape compared with
the unselected spectra presented herein. The ability to define
Fig. 1. Role of AFB1 in development of HCC. AFB1 is activated by metabo-
lism to form an electrophilic epoxide, which binds to DNA to formmutagenic
AFB1-DNA adducts. The two adducts shown, AFB1-N
7-Gua and AFB1-FAPY,
are mutagenic in vivo and cause the type of mutation that is seen most
frequently in HCCs (the G:C→T:A transversion). Shortly after dosing, it is
proposed that a “founder” or “exposure” mutational spectrum forms. As
the tissue ages, subsequent mutational processes continue to mature the
founder spectrum into the mutational spectrum seen in end-stage cancer.
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unbiased mutational spectra is fundamental to definition of the
causative mutational processes underlying mutational landscapes.
The DS methodology (Fig. 2C) was applied to DNA extracted
from each of the tissue samples detailed in Fig. 2 A and B (i.e.,
A-10, A-72T, A-72H, D-10, D-72). DS was performed to a me-
dian depth of coverage of ∼15,000 reads per base. The total
number of nucleotides sequenced and total number of point
mutations observed are shown in Table 1. In all samples, it was
observed that certain mutations occurred repeatedly at the same
nucleotide position in the 6.4-kb target. For purposes of the
analyses below, these mutations were considered clonal in origin,
resulting from a single mutagenic event that was subsequently
amplified during cell division; these presumably clonal mutations
were counted only once per biological replicate. The basis for
this decision was the observation that despite the high mutage-
nicity of AFB1 (Table 1), the probability of the same mutation
occurring independently at the same site in two separate liver
cells or in the same cell in two separate copies of the 6.4-kb
target is only ∼0.01% (Supplemental Notes, Note 1). The rele-
vance of clonal mutations is further considered in Supplemental
Notes, Note 2. The tally of unique mutations thus obtained for
each sample (Table 1) was then grouped into the six possible
types of point mutation (Table 2).
Duplex Consensus Sequencing Detects an AFB1-Specific Mutational
Spectrum at 10 Wk After Carcinogen Administration. One objective
of this work was to use the resolution of DS analysis to capture
the unique mutagenic profile of AFB1 exposure shortly after
dosing. The liver at 10 wk postdosing, when measurements were
made, is phenotypically normal and indistinguishable from the
DMSO-treated control; it takes over a year for tumors to de-
velop in this single-dose animal model of HCC.
Consistent with previous studies (16), AFB1-treated animals
had an 11-fold higher frequency of unique mutations [mutation
frequency (MF) = 3.08 × 10−6] relative to the DMSO controls
(MF = 2.70 × 10−7). Additionally, as expected from the mech-
anism of AFB1-induced DNA damage, the spectrum at 10 wk
after toxin administration (A-10) showed a preponderance of
G:C→T:A transversion mutations, whereas the DMSO control
(D-10) featured a more diverse collection of transitions and
transversions (Table 2).
DS analysis also allowed for a more in-depth, fine-grained
analysis of mutational spectra, including the influence of se-
quence context. When the point mutations were enumerated in
all 96 possible three-base contexts (with the central base being
the one at which the mutation occurred), and their proportion
was normalized to the relative frequency of each sequence context
in the 6.4-kb target (Fig. S2), a characteristic high-resolution AFB1
exposure mutational spectrum emerged (Fig. 3A). Whereas the
expected G:C→T:A mutations dominated the mutational spectrum
10 wk after AFB1 administration, they were nonuniformly distrib-
uted across the different sequence contexts. As one example, fully
25% of all mutations were G:C→T:A occurring in the 5′-CGC-3′
context (the underlined G is the position of the mutation). By
contrast, mutations in the DMSO control spectrumD-10 were more
evenly distributed across the trinucleotide sequence contexts,
encompassing G→T and G→C transversions, as well as G→A
transitions (Fig. 3A and Table 2), with only 2% of the total muta-
tions corresponding to the 5′-CGC-3′→5′-CTC-3′ genetic change.
The observed 10-wk AFB1-induced mutational spectrum was
highly reproducible. Animal-to-animal (n = 4) and sequencing
run-to-run relative errors in the mutational spectral data were
∼4% (Fig. S3). Each of the four AFB1-treated animals analyzed
at 10 wk showed the prominent G→T hotspot at the CGC se-
quence (yellow band in the Fig. S3). Importantly, the individual
mutations that contributed to that peak were unique to each
mouse and uniformly distributed among the CGC sites across the
6.4-kb cluster (Fig. S4).
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Fig. 2. Experimental work flow. (A) Male gptΔ B6C3F1 mice were treated as
neonates with AFB1 and killed at either 10 wk (A-10) or 72 wk (A-72) of age.
D-10 and D-72 are the corresponding DMSO solvent controls. (B) Liver tissues
from killed mice at 72 wk of age were subjected to collagenase perfusion,
and hepatocytes or tumor cells were isolated (A-72H and A-72T, respectively;
D-72 is the corresponding DMSO control). (C) Overview of the DS method
used to identify mutational spectra obtained from the mice shown in A and
B. Adapted from Schmitt et al. (24). Details are provided in the main text.
CAT, chloramphenicol acetyl transferase.
Table 1. DS aggregate output for each of the animal samples analyzed
Sample
No. of
animals
Total
mutations
Unique
mutations
Percent
unique
Percent
clonal
Total nucleotides
sequenced
(×106 bp)
Mutant
fraction
(×10−6)
A-10 4 804 397 49.4 50.6 128.8 3.08
D-10 6 1,439 153 10.6 89.4 566.6 0.27
A-72H 2 224 197 87.9 12.1 52.9 3.72
A-72T 4 6,221 324 5.2 94.8 1,620.0 0.20
D-72 2 540 142 26.3 73.7 747.3 0.19
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Analysis of AFB1-Induced Mutational Spectra in Liver Tumors and
Surrounding Hepatocytes at 72 Wk. This work tested the possibil-
ity that tissue that evolves into HCC accumulates, over time, an
expanded set of genetic changes that complement those changes
present at 10 wk after AFB1 exposure. Livers bearing tumors
from 72-wk-old animals originally exposed to AFB1 were sepa-
rated into tumor tissue and adjacent hepatocyte fractions (Fig.
2B) and analyzed separately, producing the HRMS denoted
A-72T and A-72H, respectively (Fig. 3A).
The spectrum from the hepatocyte fraction surrounding the
tumor at 72 wk recapitulated the distinctive features of the early-
onset A-10 spectrum, whereas the spectrum of the tumor, A-72T,
was much more complex. The G→T in the CGC context char-
acteristic of A-10 and A-72H remained the most abundant G→T
mutation present in the A-72T tumor spectrum, reinforcing the
notion that this CGC context was an AFB1-specific mutational
hotspot. However, although still dominated by G→T mutations
(Table 2), the tumor showed enhanced mutational diversity. One
notable feature was the periodicity of G:C→A:T mutations (red
bars in Fig. 3A), which is reminiscent of signature 1 from the
work of Stratton and coworkers (27); this feature is usually at-
tributed to the deamination of 5-methylcytosine in methylated
5′-CpG-3′ sites and constitutes an example of an AFB1 adduct-
independent mutational process that may be operating during
tumor development. The DMSO control mutational spectra at
10 wk (D-10) and 72 wk (D-72) were similar to one another (Fig.
3A). They were also similar to the tumor spectrum (A-72T), with
a few notable exceptions, namely, that the G→T mutation in the
CGC sequence context hotspot is a major peak in the AFB1-
initiated tumor (A-72T) but is essentially absent in the controls
(Fig. 3A and Table 2). Similarly, the G→T in the CGG context is
present in tumor and other AFB1-treated tissues (A-10 and
A-72H), but it is not a significant feature of the control HRMS.
The relationships among the collected HRMS were evaluated
by unsupervised clustering using the metric of cosine similarity
(Fig. 3B). As expected based on the qualitative similarities ob-
served by visual inspection, the spectra at 10 and 72 wk after
AFB1 administration (A-10 and A-72H, respectively) were highly
similar (0.96 cosine similarity, where 1.00 denotes identity). The
DMSO controls (D-10 and D-72) were also similar to one an-
other (0.79 cosine similarity). The AFB1-treated tumor spectrum
(A-72T) clustered more closely with the DMSO controls (0.75–
0.76 cosine similarity) than it did with either of the two AFB1-treated
Table 2. Relative proportions of point mutations in the spectra displayed in Fig. 3
Sample G:C→T:A, % G:C→C:G, % G:C→A:T, % A:T→T:A, % A:T→G:C, % A:T→C:G, % G:C→T:A in 5′-CGC-3′ sites,* %
A-10 69 12 13 2 2 2 25
D-10 36 32 13 5 7 7 2
A-72H 59 13 23 3 2 0 25
A-72T 41 21 24 6 4 4 5
D-72 32 28 20 9 8 3 1
*The underlined G is the position of the mutation.
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Fig. 3. (A) HRMS of mice 10 and 72 wk after treatment with AFB1. The MF distributions enumerate base substitutions in each of the 96 possible three-base
contexts (the center base in each context is the site of the mutation). Sample designations are presented in Fig. 2. (B) Cosine similarity provides a quantitative
metric to express how similar the HRMSs are to one another.
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nontransformed tissues (A-10 and A-72H; 0.66–0.67 cosine
similarity). However, when considering only the G→T portion
of the spectra (blue bars in Fig. 3A), the AFB1-initiated tumor
A-72T shows an enhanced cosine similarity of 0.73–0.78 with
A-10 and A-72H. Moreover, if one compares linear combina-
tions between the A-10 and D-10 spectra with the A-72T tumor
spectrum, a maximum of 0.85 cosine similarity is reached for a
combination of 29% A-10 and 71% D-10 (Fig. S5). This result
substantiates the interpretation that the tumor spectrum at
72 wk is a composite, reflecting substantial mutagenic contri-
butions from the “pure” AFB1 spectrum (i.e., A-10), “sponta-
neous” mutagenic processes (i.e., those processes captured in
the DMSO controls), and likely additional mutagenic processes
involved in tumor development.
Additional clues regarding mutational processes captured by
A-72T can be gleaned when considering the total number of
mutations in each tumor, rather than just the unique mutations.
Although this study was not designed to investigate clonal ex-
pansion of mutations in tumors, the high sequencing depth of DS
revealed that the tumor tissues contained a large proportion of
mutations that occurred at only a few sites within the 6.4-kb se-
quenced segment (Supplemental Notes, Note 2). Given the low
probability of sibling mutations happening by chance (Supple-
mental Notes, Note 1), these data are consistent with the model of
HCC evolution as a process of clonal expansion of cells during
accelerated replicative growth. Mutations that occurred early in a
few initiated cells would propagate in the tumor, generating
hundreds or even thousands of repeat copies; by contrast, muta-
tions that occurred late in tumor growth (i.e., during the last few
cell divisions) would have a low clonality. Fig. S6 shows the ag-
gregate sequence data (total number of mutations) for each of the
four tumors both as the distribution of mutations across the 6.4-kb
target and as the distribution of mutations across the 96 possible
triplet sequence contexts. Looking at the summary data (Fig. S7),
it is remarkable that the mutations substantially amplified (i.e.,
more than 100 copies) by clonal expansion were mainly G:C→T:A
and G:C→A:T mutations. The clonal G→T mutations were found
primarily at GGC and CGC sites, suggesting an AFB1 origin (Fig.
3A), whereas the clonal G→A mutations occurred predominantly
in CGN sequence contexts, suggesting a spontaneous origin (e.g.,
signature 1 in ref. 27). The ostensibly mixed origin of these early
mutations observed in the AFB1-induced tumors lends further
credence to the notion that the tumor spectrum A-72T reflects
multiple mutagenic processes, an important one of which includes
AFB1 adduct-induced mutagenesis.
The A-10 HRMS Constitutes a Biomarker of Exposure to AFB1 that
Recapitulates the Mutagenic Landscape of AFB1-Induced Human
HCC. Exome sequencing of human HCC by Schulze et al. (28)
recently revealed the mutational portraits of 243 tumors. The
complexities and idiosyncrasies of human life make it difficult to
attribute the etiology of an end-stage tumor to specific causes, be
they genetic or environmental. Nevertheless, clustering analysis
based on genetic and other criteria revealed a subgroup of tu-
mors that these authors posited to have been induced by expo-
sure to AFB1. This conclusion was based on (i) the prevalence of
G→T mutations in these tumors, (ii) the hepatitis B-positive
status of many members of the cohort (viral hepatitis syner-
gizes with AFB1 in the most severe cases of HCC), and
(iii) metadata that suggested likely exposure to dietary AFB1.
Cohort members were nonsmokers (smoking, like AFB1, causes
G→T mutations) and lacked alcoholic hepatitis as a risk factor.
Our work used an animal model in which AFB1 was the sole
agent to induce HCC, and thus provided A-10 as a definitive
“exposure mutational spectrum” of this toxin. Accordingly,
A-10 is a suitable reference spectrum for evaluating the HCC
samples from humans who are presumed, but not known with
certainty, to have been exposed to the toxin. The utilization of
an experimentally derived spectrum as a biomarker of exposure
for AFB1 significantly diminishes the uncertainty involved in
assigning the environmental etiology of a given human tumor.
We combined the mutational data for the 243 human HCCs
described by Schulze et al. (28) with more recent data for an
additional 71 HCCs from the Catalogue of Somatic Mutations in
Cancer (COSMIC), The Cancer Genome Atlas, and INSERM
repositories. For each HCC sample, the mutations were tallied
and organized by the trinucleotide sequence context in which
they occurred using available patient-specific reference genome
information. The resulting mutational spectra were subsequently
normalized by the frequency of occurrence of each trinucleotide
sequence context relevant for each sample (e.g., for samples
acquired by whole-exome sequencing, the frequency of trinu-
cleotides in the human exome was used). Following the addition
of the HRMS spectrum from AFB1-treated liver 10 wk after
toxin administration (A-10; Fig. 3A) to this dataset, an un-
supervised clustering analysis was performed using cosine simi-
larity and a weighted pair group method with arithmetic mean
analysis. It was our hypothesis that the tumor samples dominated
by mutations induced by AFB1 would cluster together with our
A-10 AFB1 exposure HRMS.
The results of the unsupervised clustering analysis revealed a
group of 13 human tumors that cluster with the A-10 spectrum
(red/blue box in Fig. 4A). The five human HCC spectra most
similar to the A-10 murine spectrum (on the basis of cosine
similarity; the central cluster in Fig. 4C) are shown individually
alongside A-10 in Fig. 4B, and visual inspection reveals the
similarity between these six spectra. The characteristic features
of A-10 are prominent features in each of the five human
spectra: (i) the abundance of G:C→T:A mutations, dominated
by the mutation in the CGC sequence context in most cases;
(ii) a comparatively minor fraction of G:C→A:T mutations; and
(iii) the absence of significant amounts of other types of muta-
tions. Importantly, four of the five human samples in our cluster
of Fig. 4B were present in a five-sample group identified by
Schulze et al. (28) as MSig2. MSig2 is the principal dataset used
to construct the computationally derived mutational signature
anticipated for AFB1-exposed humans, called Signature 24 (28).
The cosine similarity matrix for all 13 tumor spectra, as well as
for A-10, is shown in Fig. 4C. The mouse spectrum 10 wk after
AFB1 administration, A-10, is embedded deep in the dendro-
gram tree of the cluster, which underscores how closely its fea-
tures match the features of its human neighbors. Additionally, as
anticipated above, the five human spectra of Fig. 4B show es-
pecially high cosine similarities (0.79–0.91) to the mouse 10-wk
spectrum, A-10 (Fig. 4C).
Discussion
It has been a long-standing goal of cancer genetics to provide
insights into the evolutionary changes that portend tumor de-
velopment before overt clinical symptoms appear. This goal is
especially crucial for hepatocarcinogenesis, because liver tumors
show few clinical symptoms until the disease has reached a late,
usually fatal, stage. Early-onset biomarkers might enable in-
tervention to eliminate or curtail development of the disease.
Our work used DS to sequence DNA at very high depth, re-
vealing the HRMS of AFB1 shortly after toxin administration.
The spectrum 10 wk after exposure, A-10, is an early biomarker
for AFB1 exposure. Given the particularities of the single-dose
carcinogen model used (early carcinogen exposure followed
quickly by rounds of replication that converted the mutagenic
adducts into mutations), the A-10 spectrum is anticipated to
reflect primarily the unique mutagenic imprint of AFB1 expo-
sure. Although A-10 reflects, at minimum, prior AFB1 exposure,
it is also permanent in that this signature is still clearly visible in
nontumor cells of the liver at the point in time when tumors
are abundant.
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The level of detail in the mutational spectra of AFB1-treated
liver allows chemical insight into the events that generate specific
features of the mutational patterns. The G:C→T:A dominance in
the spectra was expected due to the mutational properties of
individual AFB1-DNA adducts (all of which occur at guanines)
(12, 13, 29, 30), the mutational spectra in vitro and in vivo of
AFB1 in cells and tissues (12–18), and observed patterns of
mutations in human tumors (27, 28). Unexpected, however, was
the high G→T mutation yield at selected guanyl residues in the
16 possible three-base contexts (Fig. 3A). Indeed, the hotspot at
the CGC sequence was at least three- to fourfold more abundant
than the next most frequent mutation. The mutations at CGC
sequences are both robust (they occur at a majority of CGC sites
present throughout the 6.4-kb target; Fig. S4) and very re-
producible across biological replicates (Fig. S4). Several reasons
could explain the context-dependent mutagenic pattern observed
in the G→T domain of Fig. 3. First, there is evidence that some
guanine three-base contexts (e.g., CGC) are better targets for
covalent bonding with AFB1 than others. Previous data on the
propensity of AFB1-epoxide to alkylate DNA suggest that G:C-rich
sequences, a guanine flanked by G:C base pairs, tend to be
preferentially modified (9). In fact, CGC is the third most re-
active sequence toward the AFB1-epoxide. Second, an adduct in
some contexts might evade repair better than an adduct in other
contexts (e.g., an AFB1 adduct at a TGT site may be repaired
better than one at CGC); such an outcome was observed with
DNA alkylation damage (31). Third, an adduct in the CGC
hotspot context could be misreplicated by a polymerase more
often than the same adduct in another context. Any or all of
these three possibilities could result in the uneven mutational
spectrum of AFB1.
As an additional factor relevant to adduct formation and re-
tention, the λ-EG10 transgene in our mouse model is not expressed,
and it has been suggested that its CpG sites are predominantly
methylated (32). Therefore, the observed hotspot in A-10 may re-
flect strong AFB1 binding and weak repair at a methylated CGC
sequence. To date, in vitro studies have provided contradictory
evidence as to whether the presence of a 5-methylcytosine adjacent
to a guanine enhances reactivity toward the AFB1-epoxide (33, 34).
It is also possible that an AFB1 adduct, once formed in a methylated
CpG site, is refractory to repair, because methylated sites are often
bound by regulatory proteins (e.g., MBD4) (35). Taken together,
the hot and cold spots for mutation identified in this work will guide
the design of further experiments that will provide mechanistic in-
sights into the pathways by which AFB1 adducts site-specifically
form and are removed in vivo.
By contrast with the surrounding hepatocyte fraction, the muta-
tional spectra of tumor tissues at 72 wk (A-72T) displayed a wide
array of mutations, although still showing evidence of G→T hotspots
(e.g., in CGC and CGG contexts). However, these hotspot mutations
in the tumor at 72 wk are obscured somewhat by a broader array of
less context-dependent G:C→T:A mutations. As the tumor develops,
it is possible that inflammation and oxidative stress occur to form 7,8-
dihydro-8-oxoguanine and related products (36) that would cause
G→T mutations, perhaps in a different context-dependent manner
than seen in A-10. Also noteworthy in the AFB1-initiated tumor are
enhanced relative levels of G:C→C:G mutations, which could also
be inflammation-dependent [e.g., the oxidative stress-induced
guanidinohydantoin, spiroiminohydantoin, and imidazolone le-
sions cause this mutation type (36)]. Moreover, etheno-adducts
from lipid oxidation cause a wide range of mutation types (36),
A
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Fig. 4. Comparison of the mutational patterns of human liver cancer with the murine AFB1 exposure spectrum. (A) Dendrogram showing the results of
unsupervised clustering of 314 human HCCs and murine spectrum A-10. The red cluster indicates the 13 human HCC samples with closest cosine similarity to
A-10 (the blue vertical stripe). (B) HRMS of A-10 and the mutational spectra of the five human HCCs most similar to A-10 identified in A. The yellow stripe
highlights the G:C→T:A hotspot in the 5′-CGC-3′ context. All five humans harbored TP53 mutations, and four specifically carried the TP53.R249S mutation.
(C) Cosine similarity matrix of the red cluster from A with the murine spectrum A-10. The numbers in the matrix (also the darkness of the shade of blue)
indicate the cosine similarity between compared samples. Asterisks on the bottom of the matrix indicate TP53 status (*known mutation in TP53, but not at
position 249; **TP53.R249S mutation; no asterisk indicates TP53 wild type or status unknown).
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which could also diversify the mutational spectrum of the toxin-
induced tumor at 72 wk.
Another prominent feature of all of the mutational spectra oc-
curs in the G:C→A:T domain (Fig. 3A). A recurring pattern of
transitions occurs, spotlighted by broken lines. There are several
possible chemical explanations for this mutation. First, Bailey et al.
(13) defined the mutagenic properties of a single AFB1-N
7-Gua
adduct in the 5′-CpG-3′ context and found that the adduct mainly
causes a targeted G→T at the site of the adduct (underscored), but
that 10% of the mutations are C→T at the 5′ cytosine. The semi-
targeted mutation in this specific context is consistent with Fig. 3A.
As a second model, deamination of 5-methylcytosine residues (to
thymines) in methylated CpG sites is a well-established cause of
C→Tmutations. As mentioned above, the viral cassette is presumed
to be methylated at most CpG sites (30). This mutational signature
is thought to be triggered by the biochemical processes associated
with aging and, in addition, is a nearly universal feature seen in all
types of human cancer (27). Lastly, it is also possible that tumor
development may trigger an innate immune response, inducing
cytosine deaminases, such as apolipoprotein B mRNA editing en-
zyme, catalytic polypeptide-like (APOBEC), which would also
cause G:C→A:T mutations in certain sequence contexts (37).
In addition to providing chemical insight into the molecular
details of aflatoxin carcinogenesis, the current study highlights
the usefulness of an animal model to help inform human cancer
epidemiology. Epidemiologists have uncovered multiple risk
factors for HCC, which include, in addition to AFB1 exposure,
alcohol use, as well as hepatitis B and C and other infections.
However, epidemiological identification of risk factors is usually
based on retrospective studies. The advantage of an animal
model is that it can prospectively examine known variables, such
as AFB1 exposure, to determine the biological plausibility that
the variable contributes to the mutational processes operative in
a given human cancer. Pursuant to this point, a striking conclu-
sion of this work is that the mutational spectrum in the livers of
AFB1-treated mice 10 wk after toxin administration shows re-
markable similarity to the mutational spectra of an important
subset of human liver tumors (Fig. 4).
A number of factors could explain the similarity between the
murine spectrum A-10 and the spectra of the 13 human HCC
samples. In the infant mouse, AFB1 forms strongly mutagenic
adducts during an early-life period of rapid replicative growth (15,
16), resulting in the efficient conversion of adducts into mutations;
these early mutations likely constitute the bulk of the genetic
events depicted in A-10. By contrast to the single-dose mouse
model, the liver cells of chronically exposed humans suffer re-
peated, but probably sublethal, insults from dietary AFB1. How-
ever, the mutagenic AFB1 adducts are very persistent in mammals
and accumulate in the liver with continued exposures (10). When
a subsequent toxic insult (e.g., hepatitis B virus infection) triggers
cell death, the replicative capacity of the liver responds to restore
cell number (20). Repeated AFB1 exposures in the presence of
regenerative growth over an extended period would be expected
to produce a mutational pattern similar to A-10.
Among the many genetic changes that associate with HCC,
mutations in TP53, which often compromise the ability of this
transcription factor to stop cell cycle progression and allow DNA
repair, are the most common (17). Compromised TP53 function
could thus accelerate the mutagenic bypass of the persistent
AFB1 adducts, resulting in a mutational pattern similar to A-10.
A common TP53 oncomutation in HCC is TP53.R249S, identi-
fied in 25% of AFB1-associated human tumors (38–41) and in
24% of all HCCs cataloged by the COSMIC (42). Interestingly,
when considering all nonsynonymous amino acid changes due to
point mutations that occur in a minimum of four tumor samples
of our dataset of 314 HCC samples, the only mutated residue
with significant enrichment in the AFB1 cluster (Fig. 4) is the
TP53.R249S mutation (P value = 3.32 × 10−4, binomial test, false
discovery rate adjustment). The TP53.R249S mutation is found
in 54% (seven of 13) of the tumors in our AFB1 cluster, but
appears in only 5.1% of the 314 HCC samples. Taken together,
the current data lend support to the model that the TP53.R249S
mutation has special significance in the development of tumors
associated with AFB1 damage to the genome.
The founder mutational spectrum of AFB1 (A-10), with its
reproducible pattern of hot and cold spots, affords several op-
portunities to the fields of molecular epidemiology and cancer
prevention. With regard to epidemiology, the exposure spectrum
is durable, in that its features are undiminished over the lifetime
of the exposed animal (A-72H), and subfeatures (the CGC
hotspot) are also evident in the more complex spectrum of the
tumor (A-72T). The durability evidenced by the A-72H spectrum
suggests that the normal tissue surrounding the tumor might be a
good integrator of past exposures to the agent(s) that cause the
disease. Additionally, application of DS to search for the CGC
G→T hotspot in circulating cell-free DNA shed from AFB1-dam-
aged tissues could provide an exciting adjunct to current methods
used to examine the etiology of liver cancer in humans (43).
With regard to disease prevention, exposure spectra could be
used as a metric in studies to determine how biological and lifestyle
variables influence the risk of later life disease. We note, however,
that the appearance of the A-10 spectrum in the liver is not a strict
predictor of cancer, because other factors relevant for cancer pro-
gression, such as inflammation, may be needed to drive the tissue
toward end-stage disease. This phenomenon is illustrated by a long-
standing issue in hepatocarcinogenesis, namely, the lower rate of
liver cancer in females compared with males. The currently leading
model is that estradiol production in postpubescent females pro-
vides an antiinflammatory environment that lowers ultimate cancer
risk (44). From previous work, we know that the MF attributable to
AFB1 at 10 wk of life is identical in males and females, leading to
the conclusion that later life events, most likely inflammation or
epigenetic modifications in response to the presence of a developing
tumor, accelerate male hepatocarcinogenesis (15, 16). The com-
posite spectrum of AFB1-induced tumors (A-72T) is likely em-
bedded with subspectra characteristic of the mutational processes
associated with the hypothetical inflammatory and other events that
accelerate male carcinogenesis. As with chemoprevention efforts
aimed at the AFB1 adduct-driven component of liver cancer de-
velopment (3), complementary prevention efforts could be aimed at
diminishing the inflammatory and other factors that appear to be
important in the promotion of liver tumors.
In sum, the present work highlights the usefulness of an efficient
animal model in which carcinogen-induced mutational spectra, which
typically develop in human tumors over three to five decades, can be
recapitulated, at high resolution, in as little as 10 wk. This model,
together with its powerful sequencing strategy and bioinformatics
pipeline, may constitute a valuable addition to the arsenal of tools
used to study cancer etiology, prevention, and management.
Materials and Methods
Animal Treatment. C57BL/6 gptΔ transgenic mice were a gift from T. Nohmi
(45). The gptΔ B6C3F1 mice used here were generated by breeding female
gptΔ C57BL/6J mice, which harbor an estimated 80 copies of the gpt gene on
chromosome 17, with male C3H/HeJ mice purchased from The Jackson
Laboratories. Neonatal B6C3F1 mice were injected i.p. with a single dose
(6 mg/kg) of AFB1 (Sigma) in 10 μL of DMSO (Sigma) or DMSO alone on day
4 of life. At the ages of 10 and 72 wk, mice were euthanized and liver tissue
was collected for DNA extraction. All experiments were conducted in ac-
cordance with protocols approved by the Massachusetts Institute of Tech-
nology Committee on Animal Care.
Mouse Liver Perfusion, DNA Isolation, λ-EG10 Phage in Vitro Packaging, and
Plasmid Extraction. Tumor tissues were separated from nontumor cells by
perfusion of livers with a collagenase-containing solution, and both were
harvested for analysis. Tissues were pulverized in liquid nitrogen, and
genomic DNAwas extracted from ∼25mg of liver tissue using the RecoverEase
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DNA Isolation Kit (Agilent Technologies) following the manufacturer’s direc-
tions. The λ-EG10 phages were packaged in vitro from genomic DNA using
Transpack packaging extract (Agilent Technologies) following the instructions
of the manufacturer. The λ-EG10 phages rescued from genomic DNA were
transfected into Escherichia coli YG6020 expressing Cre-recombinase, gener-
ating a 6.4-kb plasmid carrying the gpt and chloramphenicol acetyltransferase
(CAT) genes. Resistant colonies were pooled after culturing cells in media
containing chloramphenicol, and plasmid DNA was isolated using a Miniprep
Kit (Qiagen) according to the manufacturer’s instructions.
Synthesis of T-Tailed Adapters Containing Degenerate Sequence Tags. Sequencing
adapters (Table S1) weremade bymodification of amethod described previously
(24, 46). Briefly, PAGE-purified, hand-mixed top and bottom strands (Integrated
DNA Technologies) were annealed; annealing involved mixing of equimolar
portions of the top and bottom strands (50 μM final concentration of each) and
heating at 95 °C for 5 min, followed by cooling to room temperature over 1 h.
The annealed product had a Y-shaped tail owing to noncomplementary ends.
The bottom (template) strand contained an 8-nt cassette of randomly inserted
bases. Extension of the 3′ terminus of the top strand converted the 8-nt single-
stranded sequence into a degenerate duplex sequence tag eventually used as a
strand discrimination marker. Extension was carried out using Klenow 3′→5′ exo-
minus DNA polymerase (New England BioLabs) at 37 °C for 1 h, and the product
was purified by ethanol precipitation. A 3′ dT overhang was created by cleavage
with HpyCH4III (New England BioLabs). Lastly, the product was again ethanol-
precipitated and resuspended to a final concentration of 15 μM. Quality control
of adapter synthesis was evaluated by 32P radiolabeling of the adapter, followed
by PAGE and autoradiography.
Library Preparations, Quality Control, and Sequencing. DNA was prepared into
libraries for DS by a modification of published protocols (24, 46). Approxi-
mately 6 μg of plasmid DNA was diluted in 130 μL of TE low buffer (Affy-
metrix) and fragmented by sonication using a Covaris S220 acoustics
ultrasonicator; the following settings were used to shear plasmid DNA to a
range of 300–350 bp: duty cycle, 10%; intensity, 6; cycles per burst, 100; time,
20 s × 5; and temperature, 4 °C. Fragmented DNA was purified with 1.0 vol
of AMPure XP beads (Beckman Coulter) following the manufacturer’s pro-
tocol. Sheared DNA was end-repaired (New England BioLabs) and 3′-end dA-
tailed using Klenow exo-minus polymerase (New England BioLabs) per the
manufacturer’s protocol. DNA fragments were purified using 1.0 vol of
AMPure XP beads. The dA-tailed DNA fragment was ligated to the dT-tailed
adapter using Quick T4 DNA ligase (New England Biolabs). The adapter-
ligated DNA product was purified with 0.65 vol of AMPure XP beads. Mul-
tiple copies of each strand of adapter-ligated DNA were created by PCR
amplification using PCR primers that incorporated sample-defining barcodes
(Table S1) using the KAPA HiFi PCR kit (Kappa Biosciences). The amount of
DNA used for amplification was adjusted to obtain an optimal peak family
size of 6 as described (24, 46). PCR products of 366–415 bp were selected
using AMpure XP beads. The size distribution and the molar concentration
of each library were determined on an Agilent Bioanalyzer. The libraries
were then sequenced using a 150-bp paired-end protocol on the NextSeq
Illumina platform according to the manufacturer’s recommendations.
Data Processing. Reads with intact duplex tags contain an 8-nt random se-
quence. The 8-nt tag sequences from both the forward and reverse sequencing
reads were computationally added to the read header to result in a combined
16-nt tag for each read. Readswere then aligned to the reference λ-EG10 phage
genome with the Burrows–Wheeler aligner (BWA), and nonmapping reads
were rejected. Reads sharing identical tag sequences were then grouped and
collapsed to consensus reads. Consensus reads were realigned with the BWA.
The consensus sequences were then matched with their strand partners by
grouping each 16-nt tag of form αβ in read 1 with its corresponding tag of
form βα in read 2. Resulting sequence positions were accepted only when
information from both DNA strands was in perfect agreement.
HRMS Clustering Analysis with Human HCC. HRMS are the result of counting
the frequency of mutations centered in each canonical trinucleotide context
and then dividing by the frequency of trinucleotide occurrence in the 6.4-kb
reference transgene. After normalization, HRMS are rescaled to sum to 1. All
composite HRMS are the result of the arithmetic mean of each cohort’s
normalized individual HRMS.
Unsupervised hierarchical clustering of 314 human HCC samples from the
COSMIC database (v76) and A-10 was performed. HCC samples were filtered
to include only validated somatic base substitutions that were called against
the most recent release of the human reference genome in genome-wide
screens. Each mutation for each sample was associated with its tri-
nucleotide context using the pyfaidx Python module using the hg38 version
of the human genome. All samples were then normalized based on either
the frequency of the trinucleotide contexts present in the human exome or
in the whole genome. Hierarchical clustering was performed using Scipy’s
linkage and dendrogram routines with the weighted pair group method
with arithmetic mean (WPGMA) method and cosine distance metric. Clusters
were identified visually. Clinical metadata associated with samples were
acquired through the COSMIC web portal or published literature (28).
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